CBD Did Not Reduce THC-Related Attention to Cannabis Cues in a Crossover Study
Adding CBD to inhaled THC did not significantly reduce attention toward cannabis images in a crossover experiment. The study’s comparison with sober baseline suggested a THC-related change, but there was no separate THC-free placebo session to isolate that effect.
The randomized comparison concerned CBD ratios
Forty-six infrequent cannabis users completed four sessions with 10 mg vaporized THC plus 0, 10, 20 or 30 mg CBD in randomized order. Participants completed a visual-probe attention task and rated how pleasant cannabis, food and neutral images seemed.
The four active sessions tested whether different CBD:THC ratios changed outcomes while the THC dose remained fixed. The sober baseline assessment was an additional comparison; it was not a randomized session receiving a THC-free placebo.
A task measure changed without a liking change
For all attention trials combined, the THC-only condition shifted the cannabis-cue bias score by 12.2 milliseconds relative to baseline, with a 95% confidence interval of 1.2–23.3 milliseconds. Separate short- and long-presentation analyses were not statistically significant.
The measure was relative attention toward cannabis versus neutral images. It did not demonstrate that participants became more positive about cannabis: pleasantness ratings did not significantly change. Nor did the task diagnose cannabis use disorder or measure subsequent addiction.
The CBD comparisons were consistently null
No significant effect of CBD ratio appeared for cannabis or food attention scores or picture ratings. The finding remained when analyses reconsidered excluded reaction-time trials. Plasma cannabinoid measurements supported exposure to the assigned CBD ratios, but their associations with these task outcomes were nonsignificant.
A null result at these doses does not prove that every possible CBD schedule has no effect. It does mean that adding CBD at the tested ratios did not provide evidence of protection on this endpoint.
Selection and controls limit the broader claim
Sixty-four people were randomized, but only 46 completed the experiment. Twelve dropped out because of unpleasant drug effects. The available outcome data required a per-protocol analysis, so findings may not represent people who could not tolerate the sessions.
The authors identify the lack of a THC-free placebo condition as a limitation. Practice, visit and baseline differences therefore require consideration when attributing the baseline-to-THC contrast solely to THC. By contrast, the randomized within-person CBD-ratio comparison more directly addresses the CBD question.
This distinction prevents two overstatements: calling attention bias a proven future disorder, and claiming that a CBD-rich cannabis product necessarily neutralizes THC’s behavioral effects.
Related analysis: Concentration Is Not Impairment: THC Blood Levels in California Driving Cases.
Primary research
Dominic Oliver and colleagues. Cannabidiol does not attenuate acute delta‐9‐tetrahydrocannabinol‐induced attentional bias in healthy volunteers: A randomised, double‐blind, cross‐over study. Addiction (Abingdon, England) (2023). DOI: 10.1111/add.16353.
